Why Most Invention Valuation Methods Produce Numbers Nobody Actually Believes

Ask a tech transfer officer how they valued a particular invention before licensing it, and you'll usually get one of two responses. Either a confident recitation of the 25% rule (take projected industry profits, hand a quarter to the licensor), or a vague reference to comparable deals pulled from a database that costs $15,000 a year to access. Both answers share a common problem: nobody in the room truly believes the number.

Photo by ThisIsEngineering on Pexels.

This is not a minor inconvenience. Valuation is the number that anchors every subsequent negotiation. Get it wrong, or get it credibly wrong, and you've poisoned the deal before the term sheet is drafted.

The 25% Rule Deserves Retirement

The 25% rule has a long history and essentially no scientific basis. Robert Goldscheider popularized it decades ago based on a limited sample of licensing transactions, and it has since metastasized into standard practice largely because it produces a defensible-sounding number fast. Courts have pushed back on it. The Uniloc v. Microsoft decision in 2011 explicitly called it out as inadmissible without additional evidentiary support. Yet TTOs still open conversations with it.

Why? Because alternatives require more work, more market knowledge, and more tolerance for uncertainty than most offices have bandwidth to absorb.

The income approach (discounting projected royalty streams back to present value) is theoretically sound but requires revenue projections for a product that often doesn't exist yet. Garbage in, garbage out. You're discounting fantasy. The market approach (finding comparable licenses) suffers from a different problem: real license terms are confidential, databases are incomplete, and "comparable" is doing a lot of heavy lifting when you're trying to analogize a novel RNA delivery platform to a five-year-old microfluidics deal.

What Valuation Is Actually Trying to Do

Here's the thing most valuation exercises miss. A number produced in isolation, before a licensee is engaged, serves almost no useful purpose. Real valuation is a negotiating tool. It establishes a range, signals sophistication, and demonstrates that the TTO understands the commercial context well enough to be a credible counterparty.

That reframing matters because it changes what you optimize for. Rather than chasing a single defensible number, you want a range with explicit assumptions attached. State those assumptions openly. "We modeled three scenarios: conservative market penetration at 5%, base case at 12%, and aggressive at 22%. Here's what the royalty looks like in each." That conversation is more productive than presenting a single figure the licensee will immediately contest.

Scenario modeling also forces both parties to surface disagreements about the market early, before they metastasize into disputes about royalty rates mid-negotiation.

graph TD
    A[Invention Disclosure] --> B{Market Exists?}
    B -->|Yes| C[Income Approach with Scenarios]
    B -->|Emerging| D[Cost-Plus Floor + Option Structure]
    C --> E(Negotiation Range)
    D --> E
    E --> F[Term Sheet]
    F --> G((Signed License))

The Cost Floor Nobody Uses Enough

One underused anchor is the cost-to-replicate floor. What would it cost a competitor to independently develop equivalent IP, assuming they could? For genuinely novel inventions with strong patent protection, this number is often surprisingly large, and it shifts the framing from "how much should we pay for this patent" to "how much does it cost to avoid this patent."

Biotechnology is where this approach has the most traction. When a blocking patent covers a synthesis pathway that would take three to five years and $40 million to engineer around, the license price conversation starts differently. The floor isn't the answer, but it sets a credible lower bound that keeps negotiations from drifting into absurdity.

Who Should Be in the Room

Most TTO valuation processes are internal exercises. A committee reviews the invention disclosure, pulls a few comps, applies a rule of thumb, and arrives at an asking royalty rate. The people doing this work are rarely domain experts in the specific commercial market the invention addresses.

Bring in someone who is. A medical device licensing consultant, a retired industry BD executive, a sector-specific advisor who has actually negotiated deals in that space. The cost is real but modest relative to the value at stake. More importantly, external validation gives the TTO credibility in the negotiation itself. "We had the valuation reviewed by someone who has done 30 deals in this sector" is a sentence that changes the temperature in the room.

Valuation will never be a precise science when you're pricing something that has never been sold. The goal is producing a number grounded enough to survive scrutiny and flexible enough to reflect what the market will actually bear. Anything else is theater, and expensive theater at that.